Skip to main content
Log in

Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndrome

  • Short Report
  • Published:
Journal of Inherited Metabolic Disease

Summary

Enzyme replacement therapy (ERT) with laronidase, recombinant α-l-iduronidase, for mucopolysaccharidosis type I (MPS I) has been clinically available since April 2003. Pre-approval studies were performed on patients with the more attenuated forms of MPS I, Hurler–Scheie and Scheie syndromes. The clinical efficacy of laronidase on the severe form of MPS I, Hurler syndrome, is not well known. We present a patient with Hurler syndrome who has been treated with laronidase for 3 years. Clinically, the patient demonstrated improvement in urinary glycosaminoglycan (GAG) levels and hepatomegaly, but continued to experience decline in respiratory status, musculoskeletal and spinal involvement, and developmental skills. Overall, the benefit of ERT with laronidase in advanced Hurler syndrome appeared to be minimal in this patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J. A. Thomas.

Additional information

Communicating editor: Douglas Brooks

Electronic Supplementary Material

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thomas, J.A., Jacobs, S., Kierstein, J. et al. Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndrome. J Inherit Metab Dis 29, 762 (2006). https://doi.org/10.1007/s10545-006-0457-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10545-006-0457-y

Keywords

Navigation